mammalian
ortheoreovirus
current
investig
novel
cancer
therapeut
cellular
mechan
regul
suscept
reoviru
oncolysi
remain
poorli
understood
studi
present
evid
virion
disassembl
key
determin
reoviru
oncolysi
penetr
cell
membran
initi
infect
outermost
capsid
protein
reoviru
must
proteolyz
gener
disassembl
particl
call
infecti
subvir
particl
isvp
fibroblast
process
mediat
endolysosom
proteas
cathepsin
b
l
analyz
earli
event
infect
reovirussuscept
resist
cell
find
contrast
suscept
glioma
cell
rastransform
cell
reovirusresist
cancer
cell
untransform
cell
restrict
virion
uncoat
subsequ
gene
express
disassemblyrestrict
cell
support
reoviru
infect
vitrogener
isvp
establish
product
infect
pretreat
poli
c
prevent
infect
cancer
cell
find
level
activ
cathepsin
b
l
increas
tumor
disassemblyrestrict
glioma
cell
support
reoviru
oncolysi
grown
tumor
vivo
togeth
result
provid
model
proteolyt
disassembl
reoviru
critic
determin
suscept
reoviru
oncolysi
reovirus
member
reovirida
famili
nonenvelop
doublestrand
rna
dsrna
virus
mammalian
reoviru
commonli
found
stagnant
water
sewag
infect
wide
rang
speci
includ
chimpanze
monkey
pig
cattl
cat
sheep
mice
human
ubiqu
natur
environ
adult
previou
exposur
reoviru
evidenc
antireoviru
antibodi
immunocompet
anim
reoviru
infect
produc
clinic
symptom
viru
link
known
human
diseas
henc
design
orphan
reoviru
enter
viru
transmit
mainli
fecalor
rout
princip
infect
gastrointestin
respiratori
tract
mammal
gain
entri
target
cell
host
organ
reoviru
virion
must
undergo
proteolyt
disassembl
uncoat
uncoat
result
degrad
outermost
capsid
protein
subsequ
cleavag
underli
viral
protein
gener
infecti
subvir
particl
isvp
process
give
subvirion
particl
capac
penetr
endosomelysosom
plasma
membran
therebi
gain
entri
cytoplasm
reoviru
replic
occur
work
anim
model
suggest
natur
enter
infect
proteolyt
degrad
extracellularli
within
intestin
lumen
cell
cultur
howev
reoviru
take
advantag
endosom
lysosom
proteas
proteolyt
convers
isvp
necess
reoviru
uncoat
infect
vivo
vitro
demonstr
capac
proteas
inhibitor
block
enter
infect
mice
restrict
reoviru
uncoat
infect
cell
cultur
recent
reoviru
dear
investig
oncolyt
agent
varieti
human
cancer
review
ref
oncolyt
properti
reoviru
also
investig
clinic
trial
http
wwwoncolyticsbiotechcom
studi
reveal
reoviru
infect
cancer
cell
leav
normal
cell
rel
unaffect
atlhough
propos
reoviru
requir
activ
ra
signal
pathway
order
mediat
oncolysi
studi
demonstr
activ
ra
alon
control
suscept
cell
reoviru
infect
sever
cell
line
includ
highli
suscept
mous
fibroblast
suscept
reoviru
despit
low
level
ra
activ
ta
paf
unpublish
result
furthermor
observ
addit
proteas
cultur
medium
direct
infect
isvp
restrict
cell
render
permiss
reoviru
infect
observ
suggest
proteasemedi
disassembl
reoviru
capsid
may
determin
whether
cell
tumor
permiss
reoviru
infect
may
independ
elev
ra
activ
studi
investig
requir
reoviru
uncoat
glioma
cell
line
well
cell
line
rastransform
deriv
demonstr
lack
effect
reoviru
disassembl
penetr
reovirusresist
glioma
nontransform
cell
line
proteasegener
isvp
particl
effici
infect
disassemblyrestrict
cell
reovirusresist
cancer
cell
also
find
synthet
dsrna
protect
transform
cell
infect
result
support
model
requir
proteolyt
uncoat
determin
suscept
cancer
cell
reoviru
oncolysi
find
reoviru
product
infect
mediat
vivo
oncolysi
tumor
restrict
disassembl
vitro
suggest
microenviron
tumor
cellular
environ
cancer
cell
perhap
elev
cathepsin
b
l
activ
facilit
extracellular
convers
reoviru
virion
particl
penetr
cell
membran
mediat
oncolysi
reoviru
infect
major
glioma
cell
line
line
resist
reoviru
infect
reoviru
disassembl
address
factor
resist
glioma
cell
reoviru
oncolysi
examin
reoviru
capsid
disassembl
suscept
resist
cell
label
reoviru
particl
expos
glioma
cell
line
rastransform
empti
vector
pbabetransfect
found
label
reoviru
proteolyt
process
suscept
cell
line
resist
cell
line
remov
cleavag
indic
isvp
format
readili
observ
hour
post
infect
hpi
cell
reovirusresist
cell
even
hpi
figur
process
although
minim
compar
suscept
glioma
cell
also
observ
rastransform
cell
control
figur
reoviru
disassembl
previous
report
inhibit
cell
expos
cystein
proteas
inhibitor
verifi
compound
could
also
block
reoviru
uncoat
suscept
cell
permiss
cell
expos
hour
label
reoviru
exposur
describ
found
degrad
protein
cleavag
complet
inhibit
presenc
hour
exposur
viru
figur
similar
result
obtain
subsequ
experi
western
blot
specif
reoviru
antibodi
recogn
figur
result
demonstr
proteolyt
convers
reoviru
virion
isvp
defici
cell
resist
reoviru
infect
glioma
nontransform
cell
line
ineffect
reoviru
uncoat
could
explain
part
resist
cell
infect
oncolysi
investig
whether
underli
caus
defect
disassembl
resist
cell
reflect
differ
bind
entri
viru
use
radiolabel
reoviru
compar
bind
effici
permiss
resist
cell
viru
cell
incub
label
reoviru
hour
collect
cell
lysat
quantit
measur
scintil
count
found
differ
amount
reoviru
could
bind
resist
suscept
cell
figur
cell
effici
bind
reoviru
follow
highli
suscept
glioma
cell
line
cell
reoviru
resist
glioma
cell
lowest
bind
reoviru
although
inferior
bind
glioma
cell
may
reduc
permiss
cell
reoviru
infect
virion
bind
onto
cell
moreov
bind
measur
resist
cell
suscept
rastransform
suggest
level
bind
cell
mediat
differenti
suscept
treatment
affect
level
reoviru
bind
cell
line
test
exclud
possibl
reduc
suscept
via
interfer
bind
sinc
reovirion
bind
resist
suscept
cell
next
evalu
whether
reoviru
accumul
lysosom
within
disassemblyrestrict
cell
previou
studi
describ
reoviru
capsid
disassembl
necessari
count
per
minut
expos
glioma
cell
line
well
b
rastransform
empti
vector
pbabe
radiolabel
viru
allow
bind
hour
cell
return
cell
subsequ
lyse
defin
time
point
infect
lysat
clear
debri
centrifug
supernat
submit
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
follow
autoradiographi
c
reoviru
proteolysi
suscept
cell
treat
proteas
inhibitor
sigma
vitro
process
describ
cell
expos
hour
reoviru
infect
bind
ad
cell
final
concentr
western
blot
use
specif
reoviru
antibodi
detect
perform
replic
experi
perform
c
use
nonradioact
reovirion
hpi
hour
post
infect
perfor
either
endosomallysosom
plasma
membran
thu
penetr
cytoplasm
order
label
reoviru
monofunct
dye
expos
resist
suscept
cell
grown
glass
slide
label
reoviru
immunofluoresc
perform
detect
lysosom
associ
membran
protein
frequent
use
function
marker
lysosom
result
show
suscept
glioma
cell
rastransform
cell
reoviru
present
within
area
lysosom
associ
membran
protein
stain
found
also
appear
diffus
throughout
cytoplasm
suggest
perfor
lysosom
penetr
viru
occur
cell
hand
resist
cell
disassembl
inhibit
suscept
cell
punctuat
fluoresc
pattern
observ
restrict
compart
lysosom
associ
membran
protein
indic
lysosom
local
figur
sinc
propos
reoviru
transcript
initi
viru
disassembl
core
enter
cytoplasm
cell
next
address
whether
reoviru
transcript
occur
suscept
resist
cell
use
northern
blot
quantit
approach
reoviru
transcript
hpi
detect
suscept
rastransform
cell
block
cell
treat
howev
cell
expos
isvp
presenc
transcript
detect
resist
suscept
cell
even
presenc
label
reoviru
allow
bind
cell
minim
medium
hour
cell
wash
twice
phosphatebuff
salin
lyse
sonif
buffer
sampl
subject
scintil
count
perform
triplic
b
reoviru
multipl
infect
moi
ad
hour
cell
grown
glass
slide
cell
fix
formaldehyd
immunofluoresc
lysosom
marker
lysosom
associ
membran
protein
antibodi
follow
secondari
fluorescein
isothiocyan
fitc
perform
slide
mount
dapi
mount
medium
vector
photograph
multipl
acquisit
fluoresc
zeiss
microscop
magnif
c
total
rna
cell
purifi
use
rneasi
rna
extract
kit
equal
rna
amount
subject
northern
blot
use
digoxygeninlabel
probe
posit
strand
reoviru
transcript
isvp
infecti
subvir
particl
figur
result
consist
lack
penetr
reoviru
particl
restrict
glioma
cell
line
nontransform
cell
next
examin
whether
infect
vitrogener
isvp
could
bypass
disassembl
block
result
product
infect
resist
cell
accord
model
molecular
basi
reoviru
oncolysi
ra
signal
suscept
cancer
cell
overcom
translat
block
reoviru
transcript
found
resist
nontransform
cell
therefor
model
would
predict
infect
isvp
particl
also
restrain
resist
cell
line
translat
block
contrast
found
isvp
effici
infect
resist
glioma
cell
line
nontransform
cell
figur
wherea
reoviru
protein
synthesi
reovirion
infect
appar
suscept
cell
line
rastransform
cell
treat
disassembl
inhibitor
weak
base
ammonium
chlorid
data
shown
viral
protein
synthesi
follow
isvp
infect
occur
resist
cell
line
well
suscept
cell
line
even
treat
similar
result
obtain
immunofluoresc
use
rabbit
antireoviru
antibodi
follow
fitcconjug
goat
antirabbit
igg
detect
posit
reoviru
infect
green
fluoresc
cell
figur
increas
viral
progeni
also
measur
condit
product
reoviru
infect
observ
figur
next
examin
viabil
resist
suscept
cell
follow
reoviru
isvp
infect
without
treatment
describ
previous
figur
found
proteas
inhibitor
effici
prevent
oncolysi
hpi
suscept
cancer
cell
infect
reoviru
isvp
isvp
infect
also
result
signific
decreas
viabil
reovirusresist
glioma
cell
nontransform
cell
gener
remain
viabl
hpi
final
determin
whether
abil
cell
process
reoviru
key
determin
infect
broader
rang
cell
test
reovirusresist
cell
glioma
burkitt
lymphoma
cell
line
daudi
normal
human
foreskin
fibroblast
case
found
infect
isvpsa
measur
immunofluoresc
figur
continu
metabol
sdspage
detect
viral
protein
synthesi
bromid
mtt
disulfon
assay
measur
viabilityalso
result
posit
infect
cell
lysi
figur
restrict
reoviru
disassembl
also
observ
cell
figur
right
panel
given
isvp
readili
infect
suscept
disassemblyrestrict
cancer
normal
cell
result
suggest
critic
factor
resist
level
reoviru
penetr
cytoplasm
propos
resist
reoviru
infect
direct
result
inhibit
viral
translat
contrast
data
use
isvp
show
resist
cell
ie
resist
infect
virion
support
product
infect
isvp
bypass
limit
viral
entri
uncoat
penetr
cytoplasm
examin
propos
viral
translat
block
resist
cell
assess
whether
pretreat
cell
reoviru
infect
synthet
dsrna
poli
c
potent
activ
dsrnadepend
pathway
interferon
antivir
mechan
could
inhibit
viral
protein
synthesi
found
viral
protein
synthesi
reduc
nontransform
cell
cell
pretreat
poli
c
infect
isvp
howev
exposur
dsrna
prevent
reovirusisvp
infect
suscept
transform
cell
glioma
rastransform
burkitt
lymphoma
raji
cell
line
addit
isvp
infect
reoviru
resist
glioma
burkitt
lymphoma
daudi
prevent
poli
c
treatment
figur
moreov
reoviru
exposur
cell
hour
isvp
infect
result
inhibit
viral
protein
synthesi
synthet
dsrna
provid
figur
reoviru
may
insuffici
stimul
antivir
respons
isvp
infect
cell
owe
lack
penetr
viru
data
support
gener
model
wherebi
cancer
cellsbut
normal
cellshav
defect
antivir
mechan
also
suggest
reovirusresist
cancer
cell
foremost
factor
resist
transform
cell
level
reoviru
disassembl
level
viral
messeng
rna
translat
block
normal
cell
may
benefit
addit
level
protect
provid
activ
antivir
pathway
appear
primari
resist
reoviru
resid
inabl
effici
uncoat
reoviru
inhibitor
iii
cathepsin
l
invitrogen
ad
cell
concentr
hour
lysi
equal
amount
protein
assess
cathepsin
l
b
activ
measur
fluoresc
follow
procedur
recommend
manufactur
invitrogen
result
present
percentag
total
activ
untreat
cell
measur
rel
fluoresc
unit
b
suscept
cell
treat
either
cathepsin
b
l
inhibitor
hour
infect
reoviru
isvp
moi
reoviru
oncolysi
assess
mtt
hour
infect
remain
viabil
present
character
proteolyt
requir
suscept
cancer
cell
reoviru
first
investig
proteas
cathepsin
b
l
report
mediat
reoviru
disassembl
permit
reoviru
infect
addit
proteas
implic
progress
variou
cancer
includ
glioma
elev
ra
activ
cell
determin
whether
cathepsin
b
l
critic
promot
permiss
reoviru
suscept
cell
line
reovirussuscept
cell
treat
untreat
hour
cathepsin
b
l
inhibitor
iii
invitrogen
lyse
equal
amount
protein
sampl
assay
cathepsin
b
l
proteas
activ
respect
inhibitor
strongli
imped
activ
respect
proteas
also
inhibit
effect
activ
cathepsin
figur
found
inhibit
cathepsin
b
l
hour
reoviru
infect
significantli
protect
suscept
cell
reoviru
oncolysi
hpi
figur
combin
inhibitor
strongest
effect
block
reoviru
oncolysi
suscept
cell
line
rastransform
anticip
isvp
infect
unaffect
inhibitor
furthermor
result
specif
cathepsin
find
protect
infect
cell
line
treat
broadspectrum
synthet
matrix
metalloproteinas
inhibitor
data
shown
sinc
microenviron
tumor
vivo
contain
number
proteas
may
help
promot
reoviru
disassembl
decid
challeng
reovirusrestrict
cell
line
grown
tumor
mice
singl
intratumor
inject
reoviru
tumor
allow
grow
establish
palpabl
mass
challeng
plaqu
form
unit
pfu
live
reoviru
salin
intratumor
observ
lack
tumor
growth
anim
treat
reoviru
figur
hematoxylin
eosin
stain
section
show
necrosi
tumor
cell
live
reoviru
treatment
immunohistochemistri
polyclon
antireoviru
antibodi
show
presenc
reoviru
brown
tumor
uninfect
tumor
show
stain
figur
determin
level
cathepsin
b
l
activ
vivo
glioma
tumor
sampl
grown
sever
combin
immunodefici
mice
compar
respect
glioma
cell
grown
cultur
find
elev
cathepsin
activ
tumor
vivo
figur
result
provid
addit
evid
cell
line
resist
reoviru
oncolysi
vitro
render
permiss
grown
anim
may
due
proteolyt
microenviron
tumor
permiss
cell
vivo
contrast
resist
vitro
consequ
upregul
ra
vivo
set
sinc
rasgtp
level
tissu
lysat
remain
lowa
cell
grown
cultur
figur
reoviru
current
evalu
clinic
trial
novel
anticanc
therapeut
http
wwwoncolyticsbiotechcom
major
cancer
cell
line
suscept
infect
kill
reoviru
small
number
resist
spite
intens
preclin
studi
mechan
underli
suscept
cancer
cell
fulli
understood
studi
focus
hostmedi
proteolyt
reoviru
disassembl
import
mediat
suscept
use
radiolabel
fluoresc
label
reoviru
virion
infecti
subvirion
particl
found
reovirusresist
cancer
cell
nontransform
cell
restrict
infect
vitro
fail
mediat
viral
disassembl
penetr
data
show
proteolysi
reoviru
outercapsid
figur
measur
rel
fluoresc
unit
equal
amount
protein
cell
tissu
sampl
subject
ra
activ
assay
kit
describ
materi
method
rasgtp
level
measur
use
monoclon
antibodi
follow
incub
goat
antimousehorseradish
peroxidas
antibodi
visual
use
enhanc
chemiluminesc
amersham
bioscienc
protein
necessari
select
infect
kill
cancer
cell
demonstr
proteolyt
disassembl
reoviru
primari
determin
suscept
requir
revis
propos
model
call
reovirusra
model
molecular
basi
reoviru
oncolysi
accord
reovirusra
model
ra
signal
unknown
mechan
perhap
signal
releas
block
translat
viral
transcript
dsrnaactiv
protein
kinas
found
resist
cell
support
model
viral
transcript
found
equival
respect
suscept
resist
cell
howev
four
observ
inconsist
model
first
found
restrict
reoviru
uncoat
reovirusresist
cancer
cell
line
nontransform
cell
infect
reoviru
requir
disassembl
outermost
capsid
order
penetr
host
initi
viral
gene
transcript
second
found
isvp
effici
infect
reovirusresist
cell
golden
et
al
also
found
addit
proteas
media
resist
cell
render
suscept
infect
third
infect
reovirusresist
cell
isvp
prevent
cell
transform
pretreat
synthet
dsrna
reovirusra
model
predict
treatment
would
activ
pkr
result
translat
block
unproduct
infect
final
consist
ineffect
penetr
viru
resist
cell
found
lack
reoviru
transcript
resist
cell
rather
equival
level
transcript
predict
model
taken
togeth
result
suggest
reoviru
disassembl
critic
determin
oncolysi
cancer
cell
primari
factor
resist
reoviru
oncolysi
data
explain
discord
observ
led
develop
reovirusra
model
model
larg
base
studi
murin
fibroblast
transfect
high
level
oncogen
ra
never
propos
account
case
suscept
studi
demonstr
cell
low
level
bind
entri
reoviru
reovirusra
model
may
appli
directli
cell
line
ineffici
viral
entri
gener
signal
milieu
human
cancer
remain
uncertain
sinc
reoviru
infect
vast
major
cancer
cell
line
sinc
ra
activ
follow
mutat
lead
activ
ra
may
contribut
reoviru
suscept
increas
proteas
activ
eg
increas
express
reduc
express
inhibitor
otherwis
facilit
viral
entri
disassembl
studi
address
question
current
underway
laboratori
mani
virus
adenoviru
newcastl
diseas
viru
measl
sever
acut
respiratori
syndrom
ebola
etc
also
reli
proteolyt
process
capsid
envelop
protein
permit
cell
entri
replic
studi
found
specif
inhibitor
cathepsin
b
l
block
reoviru
oncolysi
broadspectrum
matrix
metalloproteinas
inhibitor
other
also
report
number
differ
proteas
cathepsin
neutrophil
elastas
typsin
other
capabl
convert
intact
reoviru
virion
isvp
enter
cell
without
addit
proteolysi
elev
proteas
express
andor
activ
common
consequ
tumorigenesi
eg
invas
angiogenesi
metastasi
consist
found
tumor
express
cathepsin
b
l
activ
vitro
counterpart
vivo
proteolyt
microenviron
may
explain
highli
resist
cell
line
becam
suscept
reovirusinduc
oncolysi
establish
tumor
vivo
three
broad
implic
studi
use
oncolyt
virus
clinic
first
encourag
effici
virus
might
enhanc
vivo
proteaserich
environ
tumor
howev
complic
predict
efficaci
base
vitro
assay
cell
resist
vitro
may
suscept
patient
second
improv
disassembl
viral
entri
may
import
strategi
employ
design
use
oncolyt
virus
clinic
use
isol
reoviru
variant
disassembl
effici
requir
cancertyp
specif
proteas
uncoat
may
increas
efficaci
reoviru
vivo
provid
specif
relat
strategi
use
measl
viru
variant
specif
engin
select
fuse
infect
cancer
cell
overexpress
metalloproteinas
final
better
understand
molecular
basi
reoviru
oncolysi
allow
us
properli
select
patient
like
benefit
treatment
optim
use
human
malign
glioma
cell
line
burkitt
lymphoma
cell
line
raji
daudi
mous
fibroblast
cell
line
cell
obtain
american
type
cultur
collect
maintain
describ
activ
ra
construct
pbabe
retrovir
vector
gener
provid
p
w
lee
dalhousi
univers
halifax
canada
transfect
select
cell
describ
dear
strain
reoviru
serotyp
intermedi
subvir
particl
obtain
describ
purifi
virion
contain
label
protein
obtain
cultur
cell
methionin
amersham
bioscienc
arlington
height
il
medium
plate
cell
hour
hpi
cell
collect
freezethaw
three
time
radiolabel
reoviru
purifi
describ
reoviru
monofunct
reactiv
dye
amersham
bioscienc
arlington
height
il
ad
purifi
reoviru
virion
particl
per
ml
incub
minut
conjug
viru
dialyz
phosphatebuff
salin
pb
ph
overnight
remov
free
dye
conjug
reoviru
fluoresc
dye
shown
yield
label
viral
outercapsid
protein
well
fivefold
decreas
viral
infect
howev
detect
signific
decreas
infect
conjug
reoviru
cell
plate
triplic
densiti
per
well
cultur
dish
incub
hour
treatment
methioninelabel
reovirion
count
per
minut
sampl
correspond
moi
ad
cell
n
minim
medium
allow
bind
cell
hour
cell
subsequ
wash
twice
pb
remov
unbound
virion
sampl
collect
lysi
cell
pb
contain
triton
sodium
deoxychol
mmoll
edta
sampl
expos
scintil
count
neg
bind
control
rabbit
polyclon
antireoviru
serum
ad
togeth
label
viru
reoviru
disassembl
analysi
cell
treat
describ
previous
bind
fresh
medium
ad
cell
return
incub
indic
time
pi
cell
wash
pb
lyse
lysat
clear
debri
centrifug
supernat
submit
sdspage
follow
autoradiographi
proteas
inhibitor
sigmaaldrich
st
loui
mo
cell
expos
cultur
medium
hour
reoviru
infect
bind
ad
cell
yield
final
concentr
western
blot
equal
amount
protein
lysat
specif
reoviru
antibodi
perform
experi
use
unlabel
reovirion
reoviru
uptak
traffick
cell
grown
slide
infect
reoviru
moi
pfucel
minimum
amount
viru
detect
fluoresc
hour
cell
subsequ
wash
pb
return
fresh
medium
hour
cell
fix
paraformaldehyd
minut
room
temperatur
follow
four
wash
pb
fix
cell
treat
goat
serum
pb
incub
mous
monoclon
lysosom
associ
membran
protein
lysosom
marker
abcam
cambridg
follow
secondari
fitcconjug
rabbit
antimous
igg
sigmaaldrich
st
loui
mo
hour
room
temperatur
cell
photograph
fluoresc
zeiss
microscop
use
multipl
acquisit
softwar
provid
zeiss
magnif
approxim
cell
cell
line
dispens
plate
glass
slide
infect
reoviru
isvp
moi
pfucel
proteas
inhibitor
sigmaaldrich
st
loui
mo
treatment
cell
expos
cultur
medium
hour
reoviru
infect
synthet
dsrna
poli
c
amersham
bioscienc
arlington
height
il
treatment
cell
expos
synthet
dsrna
medium
period
hour
reoviru
isvp
infect
viru
allow
bind
minut
ad
cell
final
concentr
metabol
label
methionin
ad
cultur
medium
hpi
period
hour
viral
protein
synthesi
assess
previous
describ
immunofluoresc
studi
cell
grown
slide
process
describ
incub
rabbit
polyclon
antireoviru
serum
dilut
pb
hour
room
temperatur
wash
incub
secondari
antibodi
fitcconjug
goat
antirabbit
igg
dilut
pb
cedarlan
hornbi
canada
hour
room
temperatur
progeni
viru
product
approxim
cell
grown
plate
infect
reoviru
moi
hpi
plate
frozen
store
use
assay
progeni
viru
product
plate
subject
three
round
freezethaw
serial
dilut
supernat
use
plaqu
titrat
cell
titrat
experi
repeat
triplic
digoxygeninlabel
riboprob
gener
plasmid
contain
open
read
frame
complementari
dna
plasmid
linear
restrict
enzym
ssai
antisens
probe
detect
posit
strand
transcript
synthes
use
polymeras
digrna
label
reagent
roch
diagnost
laval
canada
accord
manufactur
recommend
probe
precipit
ethanol
assess
qualiti
agaros
gel
electrophoresi
cell
infect
reoviru
moi
pfu
viru
allow
bind
hour
inoculum
replac
fresh
medium
put
total
cellular
rna
extract
hpi
use
rneasi
accord
manufactur
protocol
qiagen
inc
mississauga
canada
five
microgram
total
rna
resolv
agaroseformaldehyd
gel
transfer
electrophoret
overnight
hybondntm
nylon
membran
amersham
bioscienc
arlington
height
il
trisacetateedta
buffer
ph
prehybrid
hour
hybrid
carri
hour
follow
highstring
wash
ssc
sodium
dodecyl
sulfat
antidighrp
roch
use
detect
probe
use
enhanc
chemiluminesc
amersham
bioscienc
arlington
height
il
film
kodak
chalonsurchaon
franc
viabil
assay
cell
grown
confluenc
infect
reoviru
isvp
moi
cell
viabil
measur
hpi
mtt
assay
sigmaaldrich
st
loui
mo
assay
roch
diagnost
laval
canada
measur
cell
viabil
burkitt
lymphoma
daudi
cell
previous
describ
cathepsin
b
l
inhibit
activ
specif
inhibitor
cathepsin
b
inhibitor
iii
cathepsin
l
invitrogen
burlington
canada
ad
cell
concentr
hour
reoviru
infect
cathepsin
b
l
activ
suscept
resist
cell
well
tumor
tissu
quantifi
use
proteolyt
activ
kit
invitrogen
burlington
canada
accord
manufactur
protocol
sever
combin
immunodefici
mice
studi
six
eightweek
old
foxchas
sever
combin
immunodefici
mice
obtain
jackson
laboratori
bar
harbor
anim
maintain
specif
pathogenfre
condit
accord
protocol
approv
univers
calgari
anim
care
committe
xenograft
model
glioma
cell
inject
subcutan
hind
flank
mice
palpabl
tumor
establish
day
pfu
live
reoviru
pb
administ
intratumor
experiment
group
pb
administ
alon
control
group
twodimension
tumor
measur
perform
calip
everi
day
day
anim
show
sever
morbid
due
excess
tumor
burden
due
complic
aris
viral
infect
histolog
immunohistochemistri
studi
tumor
remain
mass
taken
anim
day
intratumor
reoviru
salin
inject
fix
neutral
buffer
formalin
embed
paraffin
histolog
analysi
process
describ
ra
activ
rasgtp
level
establish
human
glioma
cell
line
parent
transform
ra
cell
tumor
tissu
deriv
subcutan
cell
grown
sever
combin
immunodeficiencynonobes
diabet
mice
measur
use
ra
activ
assay
kit
upstat
biotechnolog
lake
placid
ny
accord
manufactur
protocol
describ
previous
